Quick answers
- What is Kit for the preparation of technetium tc 99M pentetate used for?
- The FDA-approved label (Draximage Dtpa, Jubilant DraxImage Inc., dba Jubilant Radiopharma, May 8, 2023) says: “DRAXIMAGE ® DTPA, after radiolabeling with Technetium Tc 99m, is indicated for DRAXIMAGE ® DTPA is a kit for the preparation of Technetium Tc 99m pentetate injection. Technetium Tc 99m pentetate is a radioactive diagnostic agent indicated for: Brain imaging in adults. Renal visualization, assessment of renal perfusion, and estimation of glomerular filtration rate in adult and pediatric patients. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the side effects of Kit for the preparation of technetium tc 99M pentetate?
- The “Adverse Reactions” section of the FDA label (Draximage Dtpa, Jubilant DraxImage Inc., dba Jubilant Radiopharma, May 8, 2023) begins: “The following adverse reactions have been identified post-approval. Because these reactions are voluntarily reported from a population of uncertain size, it is not always possible to reliably estimate their exact frequency or establish a causal relationship to Technetium Tc 99m pentetate exposure. Adverse reactions are presented in decreasing order of reported frequency: Immune system disorders: allergic reaction, anaphylactic reaction, angioedema.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Kit for the preparation of technetium tc 99M pentetate have a boxed warning?
- No. None of the 2 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Kit for the preparation of technetium tc 99M pentetate?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
- Has Kit for the preparation of technetium tc 99M pentetate been recalled?
- FDA enforcement reports list 1 recall of products of this medicine; the newest started March 19, 2020 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Kit for the preparation of technetium tc 99M pentetate?
- 2 companies list prescription products of Kit for the preparation of technetium tc 99M pentetate in the FDA NDC Directory, including Curium US LLC and Jubilant DraxImage Inc., dba Jubilant Radiopharma.
What Kit for the preparation of technetium tc 99M pentetate is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
DRAXIMAGE ® DTPA, after radiolabeling with Technetium Tc 99m, is indicated for DRAXIMAGE ® DTPA is a kit for the preparation of Technetium Tc 99m pentetate injection. Technetium Tc 99m pentetate is a radioactive diagnostic agent indicated for: Brain imaging in adults. Renal visualization, assessment of renal perfusion, and estimation of glomerular filtration rate in adult and pediatric patients. …
— FDA label: Draximage Dtpa, Jubilant DraxImage Inc., dba Jubilant Radiopharma, effective May 8, 2023. Read the full label on DailyMed →
Label quoted: the one for the most common form (injection, powder, lyophilized, for solution, intravenous), Draximage Dtpa, Jubilant DraxImage Inc., dba Jubilant Radiopharma; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.
The FDA has 2 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 2 FDA labels for this medicine have a boxed warning.
Kit for the preparation of technetium tc 99M pentetate side effects
Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.
The following adverse reactions have been identified post-approval. Because these reactions are voluntarily reported from a population of uncertain size, it is not always possible to reliably estimate their exact frequency or establish a causal relationship to Technetium Tc 99m pentetate exposure. Adverse reactions are presented in decreasing order of reported frequency: Immune system disorders: allergic reaction, anaphylactic reaction, angioedema.
Read more of this section
Skin and subcutaneous tissue disorders: rash, itching, hives, erythema. Respiratory, thoracic and mediastinal disorders: throat irritation, wheezing. Vascular disorders: hypotension, hypertension. Nervous system disorders: headache, fainting, dizziness. General disorders and administration site conditions: chills. Gastrointestinal disorders: nausea, vomiting. Cardiac disorders: cyanosis, tachycardia. Most common adverse reactions reported with Technetium Tc 99m pentetate injection include allergic reactions, rash, itching (6). To report SUSPECTED ADVERSE REACTIONS, contact Jubilant DraxImage Inc. at 1-888-633-5343 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
— FDA label: Draximage Dtpa, Jubilant DraxImage Inc., dba Jubilant Radiopharma, effective May 8, 2023. Read the full label on DailyMed →
Kit for the preparation of technetium tc 99M pentetate dosage
Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.
During preparation and handling, use water proof gloves and effective shielding, to minimize radiation exposure (2.1, 5.3). See the Full Prescribing Information for detailed information regarding recommended Dosage and Image Acquisition Instructions (2.2) and Instructions for Drug Preparation (2.4).
Read more of this section
Do not administer more than one dose (2.2). 2.1 Radiation Safety – Drug Handling Tc 99m labeled DRAXIMAGE ® DTPA injection is a radioactive drug and should be handled with appropriate safety measures to minimize radiation exposure to the patient and healthcare worker. During preparation and handling, use water proof gloves and effective shielding, including syringe shields [see Warnings and Precautions (5.3)]. 2.2 Recommended Dosage and Image Acquisition Instructions The recommended dose ranges for intravenous or inhalation administration of DRAXIMAGE® DTPA, after reconstitution, are presented in Table 1 through Table 3. Do not administer more than one dose. Table 1 Tc 99m Labeled DRAXIMAGE ® DTPA Injection – Intravenous Administration, Adults Indication Route of Administration Dose Image Acquisition Brain Imaging Intravenous Injection 370 MBq to 740 MBq (10 mCi to 20 mCi) Immediate dynamic imaging. Obtain at least one blood-pool image in same position as flow. Delayed images can be obtained 1 hour later. Renal Visualization and Perfusion Assessment Intravenous Injection 370 MBq to 740 MBq (10 mCi to 20 mCi) Immediate dynamic imaging. Static imaging 1 to 30 minutes after injection. Renal Visualization with Estimation of Glomerular Filtration Rate Intravenous Injection 111 MBq to 185 MBq (3 mCi to 5 mCi) Immediate dynamic imaging. Static imaging 1 to 30 minutes after injection. Estimation of Glomerular Filtration Rate (with no renal imaging) Intravenous Injection 7.4 MBq to 18.5 MBq (0.2 mCi to 0.5 mCi) Blood sampling only is performed. Table 2 Tc 99m Labeled DRAXIMAGE ® DTPA Injection – Intravenous Administration, Pediatric Patients Indication Route of Administration Dose Image Acquisition Renal Visualization and Perfusion Assessment Intravenous Injection 3.7 MBq/kg to 7.4 MBq/kg (0.1 mCi/kg to 0.2 mCi/kg) Minimum 37 MBq (1 mCi) Maximum 185 MBq (5 mCi) Immediate dynamic imaging. Static imaging 1 to 30 minutes after injection. Estimation of Glomerular Filtration Rate (with no renal imaging) Intravenous Injection 7.4 MBq to 18.5 MBq (0.2 mCi to 0.5 mCi) Blood sampling only is performed. Table 3 Tc 99m Labeled DRAXIMAGE ® DTPA – Aerosol Inhalation Administration * For lung imaging performed after perfusion imaging, target count rate should be approximately three times that of perfusion count rate. Indication Route of Administration Dose Image Acquisition Lung Ventilation Adults Aerosol Inhalation 925 MBq to 1850 MBq (25 mCi to 50 mCi) in the nebulizer to achieve a lung dose of approximately 18.5 MBq to 37 MBq (0.5 mCi to 1.0 mCi) For lung imaging performed prior to perfusion imaging, the target administered dose to the lungs is achieved after 3 to 5 minutes of inhalation or at an imaging count rate of 50,000 to 100,000 per minute *.
Table from the label
| Indication | Route of Administration | Dose | Image Acquisition |
|---|---|---|---|
| Brain Imaging | Intravenous Injection | 370 MBq to 740 MBq (10 mCi to 20 mCi) | Immediate dynamic imaging. Obtain at least one blood-pool image in same position as flow. Delayed images can be obtained 1 hour later. |
| Renal Visualization and Perfusion Assessment | Intravenous Injection | 370 MBq to 740 MBq (10 mCi to 20 mCi) | Immediate dynamic imaging. Static imaging 1 to 30 minutes after injection. |
| Renal Visualization with Estimation of Glomerular Filtration Rate | Intravenous Injection | 111 MBq to 185 MBq (3 mCi to 5 mCi) | Immediate dynamic imaging. Static imaging 1 to 30 minutes after injection. |
| Estimation of Glomerular Filtration Rate (with no renal imaging) | Intravenous Injection | 7.4 MBq to 18.5 MBq (0.2 mCi to 0.5 mCi) | Blood sampling only is performed. |
— FDA label: Draximage Dtpa, Jubilant DraxImage Inc., dba Jubilant Radiopharma, effective May 8, 2023. This is part of the section. Read the full label on DailyMed →
Kit for the preparation of technetium tc 99M pentetate in pregnancy
Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.
Risk Summary Limited available data with Technetium Tc 99m pentetate use in pregnant women are insufficient to inform a drug associated risk for major birth defects and miscarriage. Technetium Tc 99m pentetate is transferred across the placenta (see Data). No animal reproductive studies have been conducted with Technetium Tc 99m pentetate.
Read more of this section
All radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose. If considering Technetium Tc 99m pentetate administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from Technetium Tc 99m pentetate and the gestational timing of exposure. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S., general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2% to 4% and 15% to 20%, respectively. Data Human Data Limited published literature describes Technetium Tc 99m pentetate crossing the placental barrier. No adverse fetal effects or radiation-related risks have been identified for diagnostic procedures involving less than 50 mGy, which represents less than 10 mGy fetal doses.
— FDA label: Draximage Dtpa, Jubilant DraxImage Inc., dba Jubilant Radiopharma, effective May 8, 2023. Read the full label on DailyMed →
When Kit for the preparation of technetium tc 99M pentetate should not be used
Quoted from the “Contraindications” section of the FDA-approved label.
Hypersensitivity to the active ingredient or to any component of the product [see Warnings and Precautions (5.1)]. Hypersensitivity to the active ingredient or any component of this product (4).
— FDA label: Draximage Dtpa, Jubilant DraxImage Inc., dba Jubilant Radiopharma, effective May 8, 2023. Read the full label on DailyMed →
Forms and how it is given
| Dosage forms | Injection, powder, lyophilized, for solution |
|---|---|
| Route | Intravenous · Respiratory (inhalation) |
| Prescription products | 2 in the FDA NDC Directory |
| Brand names | Draximage Dtpa |
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Curium US LLC1 product
- Jubilant DraxImage Inc., dba Jubilant Radiopharma1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA018511 DRAXIMAGE DTPA | Jubilant | December 29, 1989 | 15, latest June 7, 2023 2023: Labeling · 2022: Manufacturing (CMC) · 2017: Efficacy |
Generic approvals (1)
- ANDA215146Curium · March 26, 2025
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
March 19, 2020 · Class II · Terminated · D-1062-2020
Failed Stability Specifications
DRAXIMAGE DTPA (KIT FOR THE PREPARATION OF TECHNETIUM TC 99M PENTETATE INJECTION), 20 mg vial, Rx only, Manufactured for: Jubilant Draximage, Inc., Kirkland, Quebec, Canada, NDC 65174-288-05, 67175-288-30 — Jubilant Draximage Inc
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
| SPL set ID of the quoted label | becdab53-f7a7-7280-6930-21f3a61b99e7 |
|---|---|
| FDA labels (SPL) | 2 |
| FDA applications | NDA018511, 1 ANDA |
| Active ingredients (FDA) | PENTETIC ACID |
Next steps
- Find a pharmacy near youAsk which price applies to you and whether your product is affected by a recall
- Latest FDA drug recallsAll medicines, newest first
- Draximage DtpaBrand page: products, maker and price
- Curium US LLCMaker or distributor
- Jubilant DraxImage Inc., dba Jubilant RadiopharmaMaker or distributor
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Draximage Dtpa, Jubilant DraxImage Inc., dba Jubilant Radiopharma, effective May 8, 2023; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →